Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Oct 31, 2022 6:39pm
190 Views
Post# 35061525

RE:RE:RE:only 3 calls left now!

RE:RE:RE:only 3 calls left now!I expect its hard for you to understand so probably why it makes no sense for you. It's OK let me help you: 

If you are interested in talking to a case manager about the COC Protocol or Avrt you can book a call thru the online calendar.  (Calendar #1)

If you are already in the Care Oncology program or are concerned about your metaboilic health and inflamation you can enter the COC Plus program it is a an additional series of blood tests (not Aristotle). (Calendar #2).

If you are interested in Aristotle cancer testing you can fill out the online form and a case manager will will call you directly.

Either of the 3 programs COC, AVRT and COC Plus will refer patients for Aristotle cancer testing or patients can go directly thru Aristotle from their doctor and than get referred to COC or AVRT or COC Plus or a combination of 2 or 3.  So there are potential cross revenue opportunities from any of the 4 programs.

Current costs in USD:

Aristotle $949
COC Protocol $925
COC Plus $330
AVRT $330



Liked2Think wrote:
LithLover wrote: You do realize they have seperate programs one stream for regular Care Oncology calls and than another for the Care Oncology Plus calls.  

They are under 2 seperate calendars:

https://careoncology.com/reserve-a-call-with-a-case-manager/

https://careoncology.com/reserve-a-call-coc/

Still want to talk about how they aren't growing. 




Liked2Think wrote: all through into next year.

must be down to one "case manager" now and they can only do 3 calls a day.

Yeah this company is nearing break even alright!

 


Great another webpage that makes no sense.

Im convinced



<< Previous
Bullboard Posts
Next >>